Cytogenetic characteristics of 328 eligible patients, by induction treatment arm
| . | AD (n = 161) . | ME (n = 167) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Evaluable | ||||
| Yes | 133 | 83 | 139 | 83 |
| No | 28 | 17 | 28 | 17 |
| Normal cytogenetics | ||||
| Yes | 52 | 39 | 51 | 37 |
| No | 81 | 61 | 88 | 63 |
| Cytogenetic risk group | ||||
| Favorable | 8 | 6 | 5 | 4 |
| Intermediate | 71 | 53 | 67 | 48 |
| Unfavorable | 52 | 39 | 64 | 46 |
| Unknown | 2 | 2 | 3 | 2 |
| . | AD (n = 161) . | ME (n = 167) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Evaluable | ||||
| Yes | 133 | 83 | 139 | 83 |
| No | 28 | 17 | 28 | 17 |
| Normal cytogenetics | ||||
| Yes | 52 | 39 | 51 | 37 |
| No | 81 | 61 | 88 | 63 |
| Cytogenetic risk group | ||||
| Favorable | 8 | 6 | 5 | 4 |
| Intermediate | 71 | 53 | 67 | 48 |
| Unfavorable | 52 | 39 | 64 | 46 |
| Unknown | 2 | 2 | 3 | 2 |
AD indicates cytarabine/daunorubicin induction; and ME, mitoxantrone/etoposide induction.